Roman S, Moore J S, Darby C, Müller S, Hoover R G
Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia 19104.
J Immunol. 1988 May 15;140(10):3622-30.
Previous reports by a number of laboratories have shown that Ig-binding factors may play a role in the regulation of Ig production by B cells. Although numerous studies have addressed the specificity and biologic function of Ig-binding factors at the cellular level, little information is available regarding the mechanism whereby Ig-binding factor modulates Ig production by B cells at the molecular level. Herein we have examined the specificity and molecular mechanism of the suppression of IgA production mediated by IgA-binding factor. Using the IgA-secreting plasmacytoma, MOPC-315, as a target cell, we have demonstrated that: 1) IgA-binding factor binds to IgA, but not to IgG, IgM, or BSA; 2) IgA-binding factor can suppress proliferation as well as IgA production by MOPC-315; 3) soluble IgA, but not IgG or IgM can inhibit the action of IgA-binding factor; 4) suppression of Ig production by IgA-binding factor is maximal within 8 to 12 h after exposure to the factor and is reversible; 5) IgA-binding factor suppresses IgA production by selectively down-regulating synthesis of IgA H and L chain proteins; 6) IgA-binding factor selectively suppresses transcription of alpha-H chain and lambda-2-L chain genes; 7) IgA-binding factor suppresses accumulation of c-myc mRNA. These findings suggest that IgA-binding factor binds selectively to surface IgA on MOPC-315 and suppresses IgA production by down-regulating transcription of H and L chain genes. Suppression of MOPC-315 proliferation by IgA-binding factor may be related to the concomitant down-regulation of the expression of the c-myc gene. c-myc is deregulated in MOPC-315 by virtue of the reciprocal 15:12 chromosomal translocation present in MOPC-315 where the c-myc gene is translocated and rearranged into the alpha-H chain gene complex. Simultaneous suppression of the expression of c-myc and alpha-H chain genes suggests that these two genes may be coordinately modulated, in plasmacytomas, by IgA-binding factor.
一些实验室之前的报告显示,Ig结合因子可能在B细胞免疫球蛋白(Ig)产生的调节中发挥作用。尽管众多研究已在细胞水平上探讨了Ig结合因子的特异性和生物学功能,但关于Ig结合因子在分子水平上调节B细胞产生Ig的机制,所知甚少。在此,我们研究了IgA结合因子介导的IgA产生抑制的特异性和分子机制。以分泌IgA的骨髓瘤细胞MOPC-315作为靶细胞,我们证明:1)IgA结合因子与IgA结合,但不与IgG、IgM或牛血清白蛋白(BSA)结合;2)IgA结合因子可抑制MOPC-315的增殖以及IgA的产生;3)可溶性IgA而非IgG或IgM可抑制IgA结合因子的作用;4)IgA结合因子对Ig产生的抑制在暴露于该因子后8至12小时内最大且是可逆的;5)IgA结合因子通过选择性下调IgA重链和轻链蛋白的合成来抑制IgA的产生;6)IgA结合因子选择性抑制α-重链和λ-2-轻链基因的转录;7)IgA结合因子抑制c-myc mRNA的积累。这些发现表明,IgA结合因子选择性地与MOPC-315表面的IgA结合,并通过下调重链和轻链基因的转录来抑制IgA的产生。IgA结合因子对MOPC-315增殖的抑制可能与c-myc基因表达的同时下调有关。由于MOPC-315中存在15:12染色体易位,c-myc基因在MOPC-315中失调,其中c-myc基因易位并重排到α-重链基因复合体中。c-myc和α-重链基因表达的同时抑制表明,在骨髓瘤细胞中,这两个基因可能由IgA结合因子协同调节。